| CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old (NCT04269213) | Roswell Park Cancer Institute | 2021-07-29 |
| Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation (NCT03602898) | Fred Hutchinson Cancer Center | 2021-06-01 |
| Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia (NCT04915612) | M.D. Anderson Cancer Center | 2021-05-21 |
| BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia (NCT04214249) | National Cancer Institute (NCI) | 2021-02-17 |
| BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia (NCT04284787) | National Cancer Institute (NCI) | 2021-02-16 |
| Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia (NCT04190550) | National Cancer Institute (NCI) | 2021-02-04 |
| Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation (NCT03953898) | National Cancer Institute (NCI) | 2020-08-04 |
| Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT03874052) | Jennifer Saultz | 2019-08-16 |
| 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome (NCT03670966) | Fred Hutchinson Cancer Center | 2019-07-10 |
| Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (NCT03813147) | National Cancer Institute (NCI) | 2019-05-17 |
| Hu8F4 in Treating Patients With Advanced Hematologic Malignancies (NCT02530034) | M.D. Anderson Cancer Center | 2019-01-31 |
| Cognitive Behavioral Therapy in Helping Patients With Acute Myeloid Leukemia or Lymphoma With Cancer-Related Fatigue (NCT03747757) | M.D. Anderson Cancer Center | 2018-11-29 |
| Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (NCT03672539) | M.D. Anderson Cancer Center | 2018-11-07 |
| Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy (NCT03630991) | M.D. Anderson Cancer Center | 2018-10-11 |
| Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia (NCT03289910) | National Cancer Institute (NCI) | 2018-09-24 |
| EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia (NCT03519984) | University of Southern California | 2018-05-09 |
| Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia (NCT03330821) | University of Southern California | 2018-04-18 |
| Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome (NCT03404193) | M.D. Anderson Cancer Center | 2018-01-18 |
| 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia (NCT03128034) | Fred Hutchinson Cancer Center | 2017-10-24 |
| Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma (NCT03096782) | M.D. Anderson Cancer Center | 2017-10-13 |
| Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent (NCT03146871) | University of Southern California | 2017-04-20 |
| Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia (NCT02953561) | M.D. Anderson Cancer Center | 2017-02-20 |
| Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT02960646) | M.D. Anderson Cancer Center | 2017-01-18 |
| Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia (NCT02658487) | Vanderbilt-Ingram Cancer Center | 2016-03-01 |
| Nivolumab in AML in Remission at High Risk for Relapse (NCT02532231) | M.D. Anderson Cancer Center | 2015-10-19 |
| 8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT02509546) | City of Hope Medical Center | 2015-09-02 |
| CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia (NCT02286726) | M.D. Anderson Cancer Center | 2015-05-04 |
| Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia (NCT02399917) | M.D. Anderson Cancer Center | 2015-04-20 |
| Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia (NCT02397720) | M.D. Anderson Cancer Center | 2015-04-07 |
| Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia (NCT01904136) | M.D. Anderson Cancer Center | 2014-04-22 |
| Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia (NCT01885689) | City of Hope Medical Center | 2014-02-10 |
| Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant (NCT02038153) | Albert Einstein College of Medicine | 2013-12-01 |
| Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies (NCT01823198) | M.D. Anderson Cancer Center | 2013-06-11 |
| Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT01664897) | M.D. Anderson Cancer Center | 2013-05-16 |
| Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia (NCT01757639) | National Cancer Institute (NCI) | 2012-12-14 |
| Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia (NCT01620216) | OHSU Knight Cancer Institute | 2012-05-11 |
| Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia (NCT01420926) | National Cancer Institute (NCI) | 2011-11-16 |
| Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT01238211) | National Cancer Institute (NCI) | 2010-12-14 |
| Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia (NCT01260714) | National Cancer Institute (NCI) | 2010-12-01 |
| Veliparib and Temozolomide in Treating Patients With Acute Leukemia (NCT01139970) | National Cancer Institute (NCI) | 2010-06-04 |
| Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia (NCT01132586) | National Cancer Institute (NCI) | 2010-05-01 |
| Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome (NCT00589316) | Fred Hutchinson Cancer Center | 2007-10-05 |
| Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia (NCT00392353) | National Cancer Institute (NCI) | 2006-11-22 |
| Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia (NCT00313586) | National Cancer Institute (NCI) | 2006-08-01 |
| Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission (NCT00093470) | National Cancer Institute (NCI) | 2004-08-18 |
| Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission (NCT00070135) | Alliance for Clinical Trials in Oncology | 2004-01-01 |